Tag Archives: BIO CEO & Investor Conference

Celgene CEO on New Multiple Myeloma Drug Approvals

BIO CEO

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Year Ahead for Business Development Events

BIO China

2013 is officially here (insert stale End-of-the-World joke). And as such, planning has been in full effect for BIO events. Here’s a recap of what’s coming up in the next few months. BIO’s in San Fran for JPM As a BIO member service, companies can schedule private meeting space for free during JP Morgan. This year, meetings will take place at The Palace Hotel, on the 5th floor. You can also find Celia, Dave, Kirsten Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Industry Outlook in Anticipation of the 2012 BIO International Convention

HC5O7460

This month, BIO wrapped the 14th Annual CEO & Investor Conference in New York City at the Waldorf=Astoria. Hosted by BIO, the event drew more than 1,200 industry leaders, featured 140 company presentations and a record breaking 1,300+ one-on-one meetings between 225 companies. Taking the momentum from this meeting, we now look ahead to the 2012 BIO International Convention to be held June 18 – 21, 2012 at the Boston Convention & Exhibition Center in Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at the Waldorf=Astoria Hotel in New York City. Meetings scheduled between institutional investors and biotech executives hit a record high and the opening plenary was a standing room only event. Kicking off the plenary were opening remarks from BIO’s Executive Vice President of Emerging Companies and Business Development, Alan Eisenberg. A copy of the slides can be found here: Opening Plenary Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

Stock Ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,